Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garadacimab prophylaxis trial in hereditary angioedema
NL-OMON50841Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of garadacimab in hereditary angioedema (HAE), sponsored by CSL Behring. Started Apr 2021; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NL-OMON50841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50841.